ECSP13012536A - Composiciones de anticuerpo y métodos de uso - Google Patents

Composiciones de anticuerpo y métodos de uso

Info

Publication number
ECSP13012536A
ECSP13012536A ECSP13012536A ECSP13012536A EC SP13012536 A ECSP13012536 A EC SP13012536A EC SP13012536 A ECSP13012536 A EC SP13012536A EC SP13012536 A ECSP13012536 A EC SP13012536A
Authority
EC
Ecuador
Prior art keywords
methods
antibody compositions
antibodies
compositions
antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Dennis
Jo-Anne S Hongo
Xiaocheng Chen
Becket L Feierbach
Ashley E Fouts
Isidro Hotzel
Bing Li
Rajesh Vij
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45890018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ECSP13012536A publication Critical patent/ECSP13012536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona composiciones que comprenden anticuerpos anti-gH y anticuerpos anti-Complejo I así como métodos de usos de las mismas.
ECSP13012536 2010-09-29 2013-03-28 Composiciones de anticuerpo y métodos de uso ECSP13012536A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38773510P 2010-09-29 2010-09-29
US38772510P 2010-09-29 2010-09-29
US201161504056P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
ECSP13012536A true ECSP13012536A (es) 2013-06-28

Family

ID=45890018

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012536 ECSP13012536A (es) 2010-09-29 2013-03-28 Composiciones de anticuerpo y métodos de uso

Country Status (21)

Country Link
US (2) US20120082666A1 (es)
EP (1) EP2621533A4 (es)
JP (1) JP2014501491A (es)
KR (1) KR20130112879A (es)
CN (2) CN104945505A (es)
AR (1) AR083214A1 (es)
AU (1) AU2011312425A1 (es)
BR (1) BR112013007514A2 (es)
CA (1) CA2811087A1 (es)
CL (1) CL2013000868A1 (es)
CO (1) CO6690799A2 (es)
CR (1) CR20130133A (es)
EA (1) EA201390467A1 (es)
EC (1) ECSP13012536A (es)
IL (1) IL225389A0 (es)
MA (1) MA34541B1 (es)
MX (1) MX2013002960A (es)
PE (1) PE20140195A1 (es)
PH (1) PH12013500616A1 (es)
SG (1) SG188657A1 (es)
WO (1) WO2012047732A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148373A1 (en) * 2012-03-28 2013-10-03 Genentech, Inc. Anti-hcmv idiotypic antibodies and uses thereof
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
EP2968503B1 (en) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
US9868777B2 (en) 2013-06-10 2018-01-16 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
WO2016049036A1 (en) * 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
ES2877532T3 (es) 2015-08-21 2021-11-17 Hoffmann La Roche Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
AU2019364823B2 (en) 2018-10-25 2025-10-30 Km Biologics Co., Ltd. Modified CMV gB protein and CMV vaccine including same
EP4396220A4 (en) * 2021-09-03 2025-10-29 Icahn School Med Mount Sinai ANTI-HCMV ANTIBODIES AND THEIR ANTIGEN-BINDING FRAGMENTS
WO2024229365A1 (en) * 2023-05-03 2024-11-07 The University Of Chicago Growth hormone targeting polypeptides
CN119269807A (zh) * 2024-11-26 2025-01-07 华润昂德生物药业有限公司 一种基于SPR检测EPO与其受体EpoR的体外结合活性的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695584B2 (en) * 1993-01-28 1998-08-20 Novartis Pharmaceutical Corporation Human monoclonal antibodies to cytomegalovirus
WO1996006625A1 (en) * 1994-08-26 1996-03-07 Eli Lilly And Company Antibody constructs with cdr switched variable regions
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EP1799262A4 (en) * 2004-10-15 2009-10-21 Seattle Genetics Inc ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
GB2429013C (en) * 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
US20080003605A1 (en) * 2006-05-24 2008-01-03 The University Of Chicago Microarray analysis of light chain variable gene expression and methods of use
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
ATE503769T1 (de) * 2006-12-15 2011-04-15 Ribovax Biotechnologies Sa Antikörper gegen das humane cytomegalie-virus (hcmv)
PT3009449T (pt) * 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes

Also Published As

Publication number Publication date
US20120082666A1 (en) 2012-04-05
CA2811087A1 (en) 2012-04-12
BR112013007514A2 (pt) 2019-09-24
EP2621533A4 (en) 2015-06-17
AR083214A1 (es) 2013-02-06
PH12013500616A1 (en) 2013-06-03
JP2014501491A (ja) 2014-01-23
US20150376265A1 (en) 2015-12-31
MX2013002960A (es) 2013-05-09
EP2621533A2 (en) 2013-08-07
PE20140195A1 (es) 2014-02-24
HK1189501A1 (zh) 2014-06-13
CL2013000868A1 (es) 2014-01-24
AU2011312425A1 (en) 2013-04-11
WO2012047732A2 (en) 2012-04-12
CN103313727A (zh) 2013-09-18
EA201390467A1 (ru) 2013-11-29
CN104945505A (zh) 2015-09-30
KR20130112879A (ko) 2013-10-14
IL225389A0 (en) 2013-06-27
WO2012047732A3 (en) 2013-05-30
SG188657A1 (en) 2013-05-31
CO6690799A2 (es) 2013-06-17
MA34541B1 (fr) 2013-09-02
CR20130133A (es) 2013-08-29
CN103313727B (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
MX2013002960A (es) Composiciones de anticuerpo y metodos de uso.
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
MX390891B (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
MX2019002979A (es) Formulaciones de anticuerpos.
CO6720984A2 (es) Anticuerpos anti-mesotelina e inmunoconjugados
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
BR112014028366A2 (pt) anticorpos anti-ly6e e imunoconjugados e métodos de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CO7121320A2 (es) Anticuerpos anti-hla-b*27 y usos de estos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
BR112014033116A2 (pt) anticorpos para tau
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
CR20110576A (es) Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
BR112014024023A2 (pt) anticorpos idiotípicos anti-hcmv e usos dos mesmos
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4